Shop
VIVADONA
₵5.13
Add to wishlist Add to compareAsk about productDescription
Vivadona is an Ayurvedic herbal supplement formulated to enhance female sexual health and address issues such as low libido, anxiety, and hormonal imbalances.
**Primary Uses:**
– **Loss of Libido:** Vivadona is indicated for women experiencing reduced sexual desire due to factors like anxiety in newly married individuals, sexual trauma, postpartum depression, and menopause. ([ayurvikalp.com](https://www.ayurvikalp.com/en-us/product/Charak-VIVADONA-20-Capsules-Enhances-Sexual-Desire-Sexual-Drive-in-Women?utm_source=openai))
– **Infertility Support:** It is used as a co-prescription in infertility counseling to improve sexual function and overall reproductive health. ([ayurvikalp.com](https://www.ayurvikalp.com/en-us/product/Charak-VIVADONA-20-Capsules-Enhances-Sexual-Desire-Sexual-Drive-in-Women?utm_source=openai))
**Drug Class:**
Vivadona is classified as a dietary supplement, not a pharmaceutical drug.
**Mechanism of Action:**
The supplement combines various herbs known for their adaptogenic, estrogenic, and aphrodisiac properties, which may help balance hormonal levels, reduce stress, and enhance sexual desire.
**Common Forms:**
Vivadona is available in capsule form, typically containing 20 capsules per pack.
**Dosage Instructions:**
The recommended dosage is 1-2 capsules twice daily, preferably after meals. It’s advisable to consult a healthcare professional before starting any new supplement regimen. ([ayurvikalp.com](https://www.ayurvikalp.com/en-us/product/Charak-VIVADONA-20-Capsules-Enhances-Sexual-Desire-Sexual-Drive-in-Women?utm_source=openai))
**Side Effects and Contraindications:**
Vivadona is generally considered safe when used as directed. However, individuals with known allergies to any of its ingredients should avoid its use. It’s important to consult a healthcare provider before starting this supplement, especially for those with existing health conditions or who are pregnant or breastfeeding.




Reviews
There are no reviews yet.